BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada.

Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company’s legacy business marketing bio and health friendly non-chemical insecticides.

BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

BioSyent sources pharmaceutical products that have been successfully developed and proven to be safe and effective; manages these products through the regulatory process and product registration (approval); and once approved, markets these products in Canada. These pharmaceuticals compete in both the branded and generic market segments and do not require further product development investment other than regulatory costs.